Cart
sales@molnova.com
Trimetazidine dihydrochloride
CAS No. 13171-25-0
Trimetazidine dihydrochloride( Trimetazidine Dihydrochloride )
Catalog No. M11287 CAS No. 13171-25-0
Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 42 | In Stock |
|
| 100MG | 61 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTrimetazidine dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent.
-
DescriptionTrimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.(In Vitro):Trimetazidine (1 μM-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induces by oxidation in a certain dose-dependent manner.(In Vivo):Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 mg/kg and 20 mg/kg doses significantly raises the seizure-threshold current in the increasing current electroshock seizure (ICES) test in the mice.
-
In VitroTrimetazidine (1 μM-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induces by oxidation in a certain dose-dependent manner. Cell Viability Assay Cell Line:Human umbilical vein endothelial cells (HUVECs)Concentration:1 μM, 10 μM, 100 μM Incubation Time:24 hours Result:Enhanced the viability of the injured HUVECs induced by oxidation.
-
In VivoTrimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 mg/kg and 20 mg/kg doses significantly raises the seizure-threshold current in the increasing current electroshock seizure (ICES) test in the mice. Animal Model:Swiss albino male mice (24-35 g)Dosage:5 mg/kg, 10 mg/kg and 20 mg/kg;10 mL/kg body weight Administration:Oral administration; 1 hour Result:In 10 mg/kg and 20 mg/kg doses significantly raised the seizure-threshold current in the ICES test.
-
SynonymsTrimetazidine Dihydrochloride
-
PathwayMetabolic Enzyme/Protease
-
TargetFatty Acid Synthase
-
Recptormitochondrial long-chain 3-ketoacyl thiolase
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number13171-25-0
-
Formula Weight339.26
-
Molecular FormulaC14H22N2O3·2HCl
-
Purity>98% (HPLC)
-
SolubilityWater: 10 mM
-
SMILESCOC1=CC=C(CN2CCNCC2)C(OC)=C1OC.[H]Cl.[H]Cl
-
Chemical Name1-[(2,3,4-Trimethoxyphenyl)methyl]piperazine dihydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kantor PF, et al. Circ Res. 2000 Mar 17;86(5):580-8.
molnova catalog
related products
-
UCM05
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) with efficacy against HER2+ breast cancer xenografts, including cell lines resistant to anti-HER2 drugs .
-
FASN-IN-2
FASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity.?TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity.
-
TVB-3664
TVB-3664 significantly decreases tubulin palmitoylation and mRNA expression. TVB-3664 is a reversible and highly bioavailable fatty acid synthase inhibitor (IC50: 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively).
